These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 22262194)

  • 41. Increased matrix metalloproteinase activity is associated with migraine and migraine-related metabolic dysfunctions.
    Bernecker C; Pailer S; Kieslinger P; Horejsi R; Möller R; Lechner A; Wallner-Blazek M; Weiss S; Fazekas F; Truschnig-Wilders M; Gruber HJ
    Eur J Neurol; 2011 Apr; 18(4):571-6. PubMed ID: 20825467
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Implication of matrix metalloproteinases in regulating neuronal disorder.
    Mukherjee A; Swarnakar S
    Mol Biol Rep; 2015 Jan; 42(1):1-11. PubMed ID: 25374425
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synaptic circuit remodelling by matrix metalloproteinases in health and disease.
    Huntley GW
    Nat Rev Neurosci; 2012 Nov; 13(11):743-57. PubMed ID: 23047773
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Levels of matrix metalloproteinases differ in plasma and serum - aspects regarding analysis of biological markers in cancer.
    Jonsson A; Hjalmarsson C; Falk P; Ivarsson ML
    Br J Cancer; 2016 Sep; 115(6):703-6. PubMed ID: 27187685
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multiplex Matrix Metalloproteinases Analysis in the Cerebrospinal Fluid Reveals Potential Specific Patterns in Multiple Sclerosis Patients.
    Castellazzi M; Ligi D; Contaldi E; Quartana D; Fonderico M; Borgatti L; Bellini T; Trentini A; Granieri E; Fainardi E; Mannello F; Pugliatti M
    Front Neurol; 2018; 9():1080. PubMed ID: 30619040
    [No Abstract]   [Full Text] [Related]  

  • 46. Matrix metalloproteinase-3 in myasthenia gravis compared to other neurological disorders and healthy controls.
    Luckman SP; Gilhus NE; Romi F
    Autoimmune Dis; 2011; 2011():151258. PubMed ID: 21826262
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Matrix metalloproteinases as biomarkers of disease: updates and new insights.
    Galliera E; Tacchini L; Corsi Romanelli MM
    Clin Chem Lab Med; 2015 Feb; 53(3):349-55. PubMed ID: 25153404
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Matrix metalloproteinases in neuropathic pain and migraine: friends, enemies, and therapeutic targets.
    Lakhan SE; Avramut M
    Pain Res Treat; 2012; 2012():952906. PubMed ID: 22970361
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The potential use of MMP inhibitors to treat CNS diseases.
    Yong VW
    Expert Opin Investig Drugs; 1999 Mar; 8(3):255-68. PubMed ID: 15992076
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Natural Marine and Terrestrial Compounds as Modulators of Matrix Metalloproteinases-2 (MMP-2) and MMP-9 in Alzheimer's Disease.
    Ciccone L; Vandooren J; Nencetti S; Orlandini E
    Pharmaceuticals (Basel); 2021 Jan; 14(2):. PubMed ID: 33498927
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Matrix metalloproteinases contribute to neuronal dysfunction in animal models of drug dependence, Alzheimer's disease, and epilepsy.
    Mizoguchi H; Yamada K; Nabeshima T
    Biochem Res Int; 2011; 2011():681385. PubMed ID: 22235372
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sex-Related Differences of Matrix Metalloproteinases (MMPs): New Perspectives for These Biomarkers in Cardiovascular and Neurological Diseases.
    Trentini A; Manfrinato MC; Castellazzi M; Bellini T
    J Pers Med; 2022 Jul; 12(8):. PubMed ID: 35893290
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Link Between Matrix Metalloproteinases and Alzheimer's Disease Pathophysiology.
    Radosinska D; Radosinska J
    Mol Neurobiol; 2024 Jun; ():. PubMed ID: 38935232
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Involvement of Matrix Metalloproteinases in COVID-19: Molecular Targets, Mechanisms, and Insights for Therapeutic Interventions.
    Salomão R; Assis V; de Sousa Neto IV; Petriz B; Babault N; Durigan JLQ; de Cássia Marqueti R
    Biology (Basel); 2023 Jun; 12(6):. PubMed ID: 37372128
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metalloproteinases as Biomarkers and Sociomarkers in Human Health and Disease.
    Costa D; Scalise E; Ielapi N; Bracale UM; Andreucci M; Serra R
    Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254696
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of matrix metalloproteinases in physiological processes & disease.
    Ravi Kanth VV; Nageshwar Reddy D
    Indian J Med Res; 2014 Nov; 140(5):585-7. PubMed ID: 25579138
    [No Abstract]   [Full Text] [Related]  

  • 57. Correlation between heavy alcohol consumption and elevation of matrix metalloproteinases.
    Forough R
    Eur J Clin Invest; 2002 Apr; 32(4):219-20. PubMed ID: 11952803
    [No Abstract]   [Full Text] [Related]  

  • 58. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in amyotrophic lateral sclerosis (ALS).
    Łukaszewicz-Zając M; Mroczko B; Słowik A
    J Neural Transm (Vienna); 2014 Nov; 121(11):1387-97. PubMed ID: 25047909
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Matrix metalloproteinase-3 in brain physiology and neurodegeneration.
    Lech AM; Wiera G; Mozrzymas JW
    Adv Clin Exp Med; 2019 Dec; 28(12):1717-1722. PubMed ID: 31851789
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metalloproteinases and Tissue Inhibitors in Generalized Myasthenia Gravis. A Preliminary Study.
    Di Stefano V; Tubiolo C; Gagliardo A; Presti RL; Montana M; Todisco M; Lupica A; Caimi G; Tassorelli C; Fierro B; Brighina F; Cosentino G
    Brain Sci; 2022 Oct; 12(11):. PubMed ID: 36358365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.